Introduction
Methods
Subjects
Investigations
Echocardiography
MRI
Plasma
Statistical analysis
Results
Baseline data
Parameter | Value |
---|---|
Age, years | 64.4 ± 14.8 |
Male sex, n (%) | 36 (83.7) |
BMI, kg/m2 | 28.1 ± 4.0 |
Creatinine | 86.88 ± 18.0 |
Hct | 0.43 ± 0.03 |
Hypertension, n (%) | 24 (55.8) |
Diabetes, n (%) | 4 (9.3) |
Statins, n (%) | 27 (62.8) |
ACE/ARB, n (%) | 20 (46.5) |
Beta-blockers, n (%) | 12 (27.9) |
Ca channel blockers, n (%) | 11 (25.6) |
Moderate AS, n (%) | 13 (30.2) |
Severe AS, n (%) | 30 (69.8) |
Bicuspid valve, n (%) | 17 (39.5) |
AV Vmax, m/s | 3.78 ± 0.48 |
MPG, mmHg | 33.74 ± 11.30 |
AVA, cm2 | 1.20 ± 0.33 |
AVAI, cm2/m2 | 0.60 ± 0.14 |
E/A | 0.91 ± 0.31 |
Septal E/e’ | 12.8 ± 3.3 |
Lateral E/e’ | 9.8 ± 3.5 |
Remodeling at 12 months
Parameter | Baseline | 12 months | p value |
---|---|---|---|
AVAI, cm2/m2 | 0.54 ± 0.15 | 0.50 ± 0.11 | 0.133 |
LVEDVI, ml/m2 | 90.7 ± 22.0 | 94.5 ± 23.1 | 0.007 |
LVESVI, ml/m2 | 38.7 ± 12.3 | 42.5 ± 13.6 | < 0.001 |
LVEF, % | 57.9 ± 4.6 | 55.6 ± 4.1 | 0.001 |
LAVI, ml/m2 | 52.9 ± 11.3 | 58.6 ± 13.6 | < 0.001 |
RVEDVI, ml/m2 | 89.0 ± 13.3 | 92.3 ± 13.5 | 0.050 |
RVEF, % | 56.8 ± 6.2 | 54.5 ± 4.6 | 0.006 |
LVMI, g/m2 | 59.1 ± 15.1 | 60.6 ± 16.0 | 0.058 |
LV mass/volume, g/ml | 0.66 ± 0.10 | 0.64 ± 0.09 | 0.231 |
Septal wall thickness, cm | 1.42 ± 0.26 | 1.39 ± 0.26 | 0.093 |
Longitudinal PSS, % | − 18.5 ± 2.8 | − 18.3 ± 2.4 | 0.537 |
Longitudinal PEDSR, 1/s | 1.06 ± 0.24 | 0.99 ± 0.24 | 0.026 |
ECV fraction, % | 24.2 ± 2.03 | 24.3 ± 4.66 | 0.929 |
Extracellular volume index, ml/m2 | 12.9 (11.4, 17.0) | 13.3 (11.1, 15.1) | 0.689 |
Cellular volume index, ml/m2 | 42.0 (37.4, 48.3) | 41.5 (36.6, 48.2) | 0.265 |
Qualitative LGE > grade 1, n (%) | 11 (26) | 20 (48) | 0.001 |
0 - Normal | 7 | 3 | |
1 - Insertion point only | 15 | 10 | |
2 - Subtle enhancement in 1 region | 2 | 9 | |
3 - Bright scar in 1 region/diffuse subtle enhancement | 7 | 8 | |
4 - Scar in multiple regions | 2 | 3 | |
Infarct pattern | 9 | 9 | |
LGE, g | 2.02 (1.26, 4.57) | 4.26 (2.17, 6.85) | < 0.001 |
LGE % LVmass | 2.25 (1.03, 4.10) | 4.20 (2.30, 6.40) | < 0.001 |
Rest MBF, ml/min/g | 0.63 (0.54, 0.78) | 0.56 (0.44, 0.62) | < 0.001 |
Stress MBF, ml/min/g | 1.34 (1.03, 1.54) | 1.08 (0.92, 1.34) | 0.002 |
MPR | 2.01 ± 0.58 | 2.17 ± 0.76 | 0.243 |
NT-proBNP, pg/mL | 43.6 (13.45, 137.08) | 53.4 (19.14, 202.20) | 0.001 |
Change in measures of fibrosis
Plasma biomarker
Associations with change in remodeling parameters
Baseline MRI parameter | Estimate (95% CI) | p value |
---|---|---|
Change in LVEDVI | ||
Baseline LV mass/volume | 40.1 (15.1, 65.2) | 0.002 |
Change in LV mass/volume | ||
Baseline LV mass/volume | − 0.32 (− 0.52, − 0.12) | 0.002 |
Baseline LAVI | 0.002 (0.000, 0.004) | 0.020 |
Change in LVEF | ||
Baseline AV Vmax | − 3.20 (− 5.76, − 0.64) | 0.015 |
Baseline PPG | − 0.10 (− 0.18, − 0.02) | 0.018 |
Baseline MPG | − 0.12 (− 0.23, − 0.01) | 0.033 |
Baseline LVEF | − 0.52 (− 0.76, − 0.29) | < 0.001 |
Change in LGE (g) | ||
Baseline LGE (g) | 0.28 (0.12, 0.45) | 0.001 |
Baseline LAVI | 0.05 (0.01, 0.08) | 0.022 |
Baseline native T1 | 0.01 (0.00, 0.02) | 0.006 |
Baseline NT-proBNP | 0.004 (0.001, 0.007) | 0.009 |